<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886713</url>
  </required_header>
  <id_info>
    <org_study_id>SLIM-HFpEF V1.0</org_study_id>
    <nct_id>NCT04886713</nct_id>
  </id_info>
  <brief_title>Adipose Tissue Inflammation in HFpEF</brief_title>
  <acronym>SLIM-HFpEF</acronym>
  <official_title>Adipose Tissue Inflammation in the Development, Maintenance and Functional Impairments in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart Center Leipzig - University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of adipose tissue inflammation in patients with heart failure with&#xD;
      preserved ejection fraction (HFpEF). Patients undergoing coronary artery bypass grafting with&#xD;
      HFpEF and without heart failure will be included in this prospective study. Epicardial,&#xD;
      paracardial, paraaortic/paravascular, subcutaneous adipose tissue samples as well as&#xD;
      myocardial tissue will be harvested during cardiac surgery. Inflammatory patterns of these&#xD;
      tissues and their relation to circulating markers will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart Failure with preserved Ejection Fraction (HFpEF) is a growing public health concern&#xD;
      with an increasing incidence, high morbidity and mortality and no proven therapy to date.&#xD;
      Better characterization of individual pathophysiological implications is mandatory to develop&#xD;
      effective therapeutic strategies or preventive programs. Obesity is an important risk factor&#xD;
      for the development of HFpEF and also modulates its course possibly by its association with&#xD;
      systemic inflammation. However, the role of adipose tissue (AT) inflammation in the&#xD;
      development, maintenance and functional impairments in HFpEF has been under-investigated.&#xD;
      Dysfunctional AT leads to a shift from a protective adipokine profile to an imbalanced&#xD;
      production of pro-inflammatory, pro-oxidant and pro-fibrotic adipokines. Besides depot&#xD;
      specific paracrine effects, the overall secretory activity or endocrine effect of AT can be&#xD;
      evaluated in peripheral plasma.&#xD;
&#xD;
      The investigators hypothesize that adipose inflammation distinguishes obese HFpEF patients&#xD;
      from obese patients without heart failure and that adipose tissue inflammation is a key&#xD;
      driver the maintenance and development of HFpEF and determines functional capacity.&#xD;
&#xD;
      In addition the investigators hypothesize that the degree of myocardial inflammatory&#xD;
      alterations is more closely related to epicardial tissue alterations than subcutaneous or&#xD;
      visceral AT tissue inflammation or peripheral adipokine profiles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adipose tissue inflammation</measure>
    <time_frame>Tissue collection during surgery.</time_frame>
    <description>Adipose tissue inflammation and distribution as well as association with adipokines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum adipokine levels</measure>
    <time_frame>At baseline, before surgery.</time_frame>
    <description>Circulating adipokine levels will be measured at a central lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI - Myocardial function</measure>
    <time_frame>At baseline, before surgery.</time_frame>
    <description>Myocardial function and extent of myocardial fibrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac MRI - Epicardial fat</measure>
    <time_frame>At baseline, before surgery.</time_frame>
    <description>Extent of epicardial fat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>At baseline, before surgery and at follow-up approximately three months after surgery.</time_frame>
    <description>Measurement of standard echocardiographic parameters of left- and right- ventricular systolic and diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity on spiroergometry</measure>
    <time_frame>At follow-up approximately three months after surgery.</time_frame>
    <description>Follow-up investigation by spiroergometry to assess post-surgical functional capacity. Measures included Peak Oxygen consumption (VO2 max) and oxygen consumption at anaerobic threshold (AT VO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress echocardiography</measure>
    <time_frame>At follow-up approximately three months after surgery.</time_frame>
    <description>Assessment of echocardiographic parameters of left- and right- ventricular systolic and diastolic function during semi-supine bicycle exercise. These measures include the change of E/E' during exercise for the left ventricle and the change of tricuspid annular plane systolic excursion (TAPSE) during exercise for the right ventricle.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese HFpEF</arm_group_label>
    <description>Left ventricular-EF ≥ 50%, N-terminal-pro-brain natriuretic peptide (NT-proBNP) ≥ 125ng/l, evidence of structural heart diseases (diastolic dysfunction, Left ventricular-hypertrophy or Left atrial-dilatation) BMI ≥30 kg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese controls</arm_group_label>
    <description>No history of heart failure, Left ventricular-EF &gt; 50% and NT-pro-BNP &lt;125ng/l, BMI ≥ 30kg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean control</arm_group_label>
    <description>No history of heart failure, Left ventricular-EF &gt; 50% and NT-pro-BNP &lt;125ng/l, BMI &lt; 30kg/m²</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Adipose and myocardial tissue sampling</intervention_name>
    <description>After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.</description>
    <arm_group_label>Lean control</arm_group_label>
    <arm_group_label>Obese HFpEF</arm_group_label>
    <arm_group_label>Obese controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging</intervention_name>
    <description>Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.&#xD;
The following imaging parameters will be acquired:&#xD;
Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume&#xD;
Biventricular mass, wall thickness&#xD;
T1 mapping; native and &gt; 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume&#xD;
Late enhancement for detection of regional fibrosis and scar&#xD;
Myocardial feature tracking for analysis of deformation/motion&#xD;
Epicardial fat volume</description>
    <arm_group_label>Lean control</arm_group_label>
    <arm_group_label>Obese HFpEF</arm_group_label>
    <arm_group_label>Obese controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiopulmonary exercise testing</intervention_name>
    <description>After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.</description>
    <arm_group_label>Lean control</arm_group_label>
    <arm_group_label>Obese HFpEF</arm_group_label>
    <arm_group_label>Obese controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stable patients with indication for coronary bypass crafting will be prospectively&#xD;
        identified at the Heart Center Leipzig (either during the admission process for patients&#xD;
        referred to surgery or at the time of coronary angiography when the indication for&#xD;
        operative revascularization is established). Patients will be grouped according to the&#xD;
        presence of HFpEF and obesity in order to generate 3 distinct patient groups, defined as:&#xD;
&#xD;
          1. Obesity HFpEF&#xD;
&#xD;
          2. Obesity Non-HF&#xD;
&#xD;
          3. Non-Obesity Non-HF&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HFpEF: Left ventricular ejection fraction ≥ 50%, NT-pro-BNP ≥ 125ng/l, evidence of&#xD;
             structural heart diseases (diastolic dysfunction, left ventricular-hypertrophy or left&#xD;
             atrial-dilatation), BMI ≥ 30kg/m²&#xD;
&#xD;
          -  Non-HF patients: No history of heart failure, Left ventricular ejection fraction &gt; 50%&#xD;
             and NT-pro-BNP &lt;125ng/l&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cardiac surgery / coronary intervention / myocardial infraction&#xD;
&#xD;
          -  Acute coronary syndrome (Serum levels of troponin T &gt;50 pg/ml)&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
          -  Indication for concomitant valvular surgery&#xD;
&#xD;
          -  Planned beating heart coronary bypass surgery&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Contraindication for magnetic resonance imaging&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  No informed consent possible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karl-Patrik Kresoja, MD</last_name>
    <phone>+49 341 865 252596</phone>
    <email>karl-patrik.kresoja@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Centre at University Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Patrik Kresoja, MD</last_name>
      <phone>0341 865 252596</phone>
      <email>karl-patrik.kresoja@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Philipp Lurz, MD, PhD</last_name>
      <email>philipp.lurz@medizin.uni-leipzig.de</email>
    </contact_backup>
    <investigator>
      <last_name>Karl-Philipp Rommel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Besler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart Center Leipzig - University Hospital</investigator_affiliation>
    <investigator_full_name>Philipp Lurz</investigator_full_name>
    <investigator_title>Clinical Investigator, Professor, Managing Senior Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

